Jundishapur Journal of Microbiology

Published by: Kowsar

Therapeutic Drug Monitoring of Voriconazole: Comparison of Bioassay with High-Performance Liquid Chromatography

Parisa Badiee 1 , Zahra Hashemizadeh 1 , * and Hashem Montaseri 2
Authors Information
1 Prof. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: April 2017, 10 (4); e45645
  • Published Online: April 18, 2017
  • Article Type: Research Article
  • Received: January 12, 2017
  • Revised: February 18, 2017
  • Accepted: February 25, 2017
  • DOI: 10.5812/jjm.45645

To Cite: Badiee P, Hashemizadeh Z, Montaseri H. Therapeutic Drug Monitoring of Voriconazole: Comparison of Bioassay with High-Performance Liquid Chromatography, Jundishapur J Microbiol. 2017 ; 10(4):e45645. doi: 10.5812/jjm.45645.

Copyright © 2017, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010; 50(8): 1101-11[DOI][PubMed]
  • 2. Badiee P, Alborzi A, Joukar M. Molecular assay to detect nosocomial fungal infections in intensive care units. Eur J Intern Med. 2011; 22(6): 611-5[DOI][PubMed]
  • 3. Shang W, Feng G, Sun R, Wang X, Liu W, Zhang S, et al. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients. J Clin Pharm Ther. 2012; 37(6): 652-6[DOI][PubMed]
  • 4. Badiee P, Alborzi A, Moeini M, Haddadi P, Farshad S, Japoni A, et al. Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods. Arch Iran Med. 2012; 15(7): 429-32[PubMed]
  • 5. Dinser R, Grgic A, Kim YJ, Pfreundschuh M, Schubert J. Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft. Eur J Haematol. 2005; 74(5): 438-41[DOI][PubMed]
  • 6. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005; 366(9495): 1435-42[DOI][PubMed]
  • 7. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag. 2007; 3(6): 1165-73[PubMed]
  • 8. Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008; 52(5): 1743-50[DOI][PubMed]
  • 9. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004; 48(2): 568-74[PubMed]
  • 10. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006; 45(7): 649-63[DOI][PubMed]
  • 11. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34(5): 563-71[DOI][PubMed]
  • 12. Badali H, Vaezi A, Aslani N, Zahedi N, Shiran MR. Overview of Voriconazole Pharmacokinetics and Pharmacodynamic Parameters. J Mazandaran Univ Med Sci. 2016; 26(136): 225-35
  • 13. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004; 75(6): 587-8[DOI][PubMed]
  • 14. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009; 65(3): 281-5[DOI][PubMed]
  • 15. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009; 53(3): 935-44[DOI][PubMed]
  • 16. Pakyz A, Bearman G. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. Consult Pharm. 2008; 23(10): 804-8[PubMed]
  • 17. Job KM, Olson J, Stockmann C, Constance JE, Enioutina EY, Rower JE, et al. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev Anti Infect Ther. 2016; 14(8): 731-46[DOI][PubMed]
  • 18. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Therapeutic drug monitoring. 2008; : 167-72
  • 19. Agrawal AK, Sherman LK. Voriconazole-induced musical hallucinations. Infection. 2004; 32(5): 293-5[PubMed]
  • 20. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008; 46(2): 201-11[DOI][PubMed]
  • 21. Wang Z, Huang CK, Sun W, Xiao C, Wang ZS. UPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2015; 29(2): 188-93[DOI][PubMed]
  • 22. H Tang P. Quantification of Antifungal Drug Voriconazole in Serum and Plasma by HPLC-UV. Journal of Drug Metabolism & Toxicology. 2013; 4(2)[DOI]
  • 23. Kahle K, Langmann P, Schirmer D, Lenker U, Keller D, Helle A, et al. Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother. 2009; 53(7): 3140-2[DOI][PubMed]
  • 24. Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother. 2000; 44(5): 1209-13[PubMed]
  • 25. Guideline on validation of bioanalytical methods. 2010;
  • 26. Europen Medicines Agency (EMA). 2014;
  • 27. Cendejas-Bueno E, Rodriguez-Tudela JL, Cuenca-Estrella M, Gomez-Lopez A. Development and validation of a fast HPLC/photodiode array detection method for the measurement of voriconazole in human serum samples. A reference laboratory experience. Enferm Infecc Microbiol Clin. 2013; 31(1): 23-8[DOI][PubMed]
  • 28. FDA guidance for industry: bioanalytical method validation. 2001;
  • 29. Badiee P, Kordbacheh P, Alborzi A, Ramzi M, Shakiba E. Molecular detection of invasive aspergillosis in hematologic malignancies. Infection. 2008; 36(6): 580-4[DOI][PubMed]
  • 30. Badiee P, Kordbacheh P, Alborzi A, Malekhoseini S, Zeini F, Mirhendi H, et al. Prospective screening in liver transplant recipients by panfungal PCR-ELISA for early diagnosis of invasive fungal infections. Liver Transpl. 2007; 13(7): 1011-6[DOI][PubMed]
  • 31. Liu L, Zhou X, Wu T, Jiang H, Yang S, Zhang Y. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China. Int J Antimicrob Agents. 2017; 49(4): 483-7[DOI][PubMed]
  • 32. Gupta H, Aqil M, Khar RK, Ali A, Chander P. A single reversed-phase UPLC method for quantification of levofloxacin in aqueous humour and pharmaceutical dosage forms. J Chromatogr Sci. 2010; 48(6): 484-90[PubMed]
  • 33. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012; 55(3): 381-90[DOI][PubMed]
  • 34. Cendejas-Bueno E, Cuenca-Estrella M, Gomez-Lopez A. Determination of voriconazole serum concentration by bioassay, a valid method for therapeutic drug monitoring for clinical laboratories. Antimicrob Agents Chemother. 2013; 57(7): 3437-40[DOI][PubMed]
  • 35. Cendejas-Bueno E, Forastiero A, Rodriguez-Tudela JL, Cuenca-Estrella M, Gomez-Lopez A. HPLC/UV or bioassay: two valid methods for posaconazole quantification in human serum samples. Clin Microbiol Infect. 2012; 18(12): 1229-35[DOI][PubMed]
  • 36. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother. 2007; 51(1): 137-43[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments